Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / Sep / Smoke Zero
Glaucoma Health Economics and Policy

Smoke Zero

Stopping smoking early in life has many benefits, including helping to manage glaucoma

By Geoffrey Potjewyd 9/16/2022 2 min read

Share

Credit: collage images sourced from Unsplash.com and Rawpixel.com

Smoking has had a rollercoaster century in scientific research, from a declaration of safety in the early 20th century to its downward trajectory after proof that it can cause lung cancer and contribute to many other health conditions. We know that smoking increases the risk and progression of glaucoma, but does stopping have any effect? Research from the Hamilton Glaucoma Center at the University of California San Diego, USA, goes some way toward answering this question, with data showing that former heavy smokers who had quit at least 25 years previously had a risk of visual field progression similar to that of people who had never smoked (1).

The researchers used data from primary open-angle glaucoma patients with the aim of observing the relationship between how early someone stops smoking and the rate of visual field progression in glaucoma – and how much early quitting can spare the optic nerve from damage. They also found that smoking intensity was associated with faster visual field loss and that heavy smokers with fewer than 25 years cigarette-free were significantly more likely to have visual field loss progression than people who had never smoked. It’s apparent that disease progression correlates with smoking intensity, and that quitting not only improves outcomes, but can turn back the clock of visual field progression risk to that of someone who has never touched a cigarette.

The pile of research suggesting that not smoking or giving it up early in life can reduce the risk of losing vision continues to grow…

References

  1. G Mahmoudinezhad et al., J Glaucoma, [Online ahead of print] (2022). PMID: 35939832.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: